Affitech Signs Strategic Alliance with Russian Biotech Partner

23-Apr-2010 - Russian Federation

NauchTekhStroy Plus (NTS Plus), a newly formed joint venture subsidiary of Pharmstandard will conduct clinical development and registration of two Affitech antibodies for Russian and CIS markets. NTS Plus will pay €23 million in fees and advanced royalties to Affitech. Pharmstandard will commercialise these antibody products in Russia and CIS. Russian Investor, Trans Nova Investments, becomes majority shareholder in Affitech by subscribing for €20.9 million in new Affitech shares.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances